<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00808964</url>
  </required_header>
  <id_info>
    <org_study_id>CLINPRO-303</org_study_id>
    <nct_id>NCT00808964</nct_id>
  </id_info>
  <brief_title>Study of NU172 as Anticoagulation in Patients Undergoing Off-pump CABG Surgery</brief_title>
  <acronym>SNAP-CABG-OFF</acronym>
  <official_title>Phase 2 Study of NU172 Anticoagulation in Patients Undergoing Coronary Artery Bypass Graft Surgery OFF-Pump</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>ARCA Biopharma, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>ARCA Biopharma, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 2, multicenter, open-label, single-arm, sequential cohort study to be
      conducted in up to 30 subjects. The study will evaluate subjects undergoing primary,
      elective, off-pump CABG surgery with median sternotomy.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Not yet recruiting</last_known_status>
  <start_date>January 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">June 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and efficacy of NU172 in patients undergoing off-pump CABG surgery</measure>
    <time_frame>30 day follow-up visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetic (PK)profile of NU172 in patients undergoing off-pump CABG surgery</measure>
    <time_frame>24 hours</time_frame>
  </secondary_outcome>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Heart Disease</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>NU172</intervention_name>
    <description>NU172 administered IV bolus followed by continuous infusion during CABG surgery</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Must give written informed consent prior to initiation of any study related procedures

          -  Male or female subjects at least 18 years of age

          -  Subject is accepted for primary, elective off-pump CABG surgery with planned
             sternotomy without other planned concomitant cardiac surgical procedures

          -  New York Heart Association (NYHA) Class III or less heart failure

          -  Available for follow-up assessments

        Exclusion Criteria:

          -  Prior surgery with median sternotomy

          -  Prior CABG surgery

          -  Women of childbearing potential who are not using adequate contraceptive precautions
             (e.g. intrauterine device, oral contraceptives,barrier methods, or other contraception
             deemed adequate by the investigator); women who are pregnant or lactating

          -  Stroke within the previous 6 months

          -  History of stroke with residual neurological deficit

          -  Intracranial neoplasm, arteriovenous malformation or aneurysm

          -  Any prior exposure to NU172

          -  Contraindication to unfractionated heparin

          -  Refusal to undergo blood transfusion, should it be necessary

          -  Symptomatic gout

          -  Serum uric acid &gt;11mg/dL at screening

          -  Known bleeding diathesis

          -  Known thrombotic diathesis

          -  Participation in any study of an investigational device, drug or biologic within 30
             days prior to planned surgery

          -  Any other disease or condition that, in the judgment of the investigator would
             interfere with the subject's ability to comply with study procedures and requirements
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicholas Smedira, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Cleveland Clinic</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Monique Plamondon</last_name>
    <phone>720-940-2125</phone>
    <email>monique.plamondon@arcabiopharma.com</email>
  </overall_contact>
  <verification_date>June 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 12, 2008</study_first_submitted>
  <study_first_submitted_qc>December 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 16, 2008</study_first_posted>
  <last_update_submitted>June 8, 2011</last_update_submitted>
  <last_update_submitted_qc>June 8, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 10, 2011</last_update_posted>
  <responsible_party>
    <name_title>Michael Bristow, M.D., PhD</name_title>
    <organization>ARCA biopharma, Inc.</organization>
  </responsible_party>
  <keyword>CABG</keyword>
  <keyword>anticoagulant</keyword>
  <keyword>Off-Pump CABG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

